Company profile
Syros Pharmaceuticals, Inc.
OTC: SYRS · Healthcare · Biotechnology
#635 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 50GM —SS 37
v0.1 · 25/100 weight · pillars only
↑ filing timeliness, workforce scale · ↓ Piotroski F, market scale
Methodology →Revenue TTM
$386.0k
Rev growth YoY (TTM)
-90.5%
Net income (FY)
-$164.6M
Employees
68
as of 2026-08-30
Market cap
$2.7k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$9.9M$9.9M2023
Net income-$164.6M-$164.6M2023
Operating income-$129.0M-$129.0M2023
Total assets$168.2M$168.2M2023
Equity$16.7M$16.7M2023
Revenue trend
FY2019 – FY2023 · USD
FY19
FY20
FY20
FY20
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Syros Pharmaceuticals, Inc.’s revenue?
Syros Pharmaceuticals, Inc. booked $9.9M in FY2023 revenue, contracting 33% year over year — slower than 76% of Healthcare companies we track, at a -1656.3% net margin.
Peers · Healthcare
Khiron Life Sciences Corp.——Zenas BioPharma, Inc.33DJanux Therapeutics, Inc.54DStablecoin Development Corp.44DTaysha Gene Therapies, Inc.48DCalithera Biosciences, Inc.——Neighbors
Middlesex →Key facts
CEOJames E. Bradner
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeOTC: SYRS
Employees68
IPO date2016-06-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.